Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia

Blood

Volumn 124, Issue 16, 2014, Pages 2611-2612

  Finazzi, Guido ^a   Carobbio, Alessandra ^a   Guglielmelli, Paola ^b   Cavalloni, Chiara ^c   Salmoiraghi, Silvia ^a   Vannucchi, Alessandro M ^b   Cazzola, Mario ^c   Passamonti, Francesco ^d   Rambaldi, Alessandro ^a   Barbui, Tiziano ^a  

^a Hospital Papa Giovanni XXIII   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JANUS KINASE 2;

CARDIOVASCULAR RISK; FOLLOW UP; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; INTERMEDIATE RISK POPULATION; LETTER; LEUKOCYTE COUNT; POLYMERASE CHAIN REACTION; RISK FACTOR; THROMBOCYTHEMIA; THROMBOSIS; ADULT; AGED; COMPLICATION; FEMALE; GENETICS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CALRETICULIN; FEMALE; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOSIS;

EID: 84908121896     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-596676     Document Type: Letter

References (7)

1. Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120(26):5128-5133, quiz 5252.
2. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
3. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391-2405.
4. Rumi E, Pietra D, Ferretti V, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544-1551.
5. Rotunno G, Mannarelli C, Guglielmelli P, et al; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552-1555.
6. Gangat N, Wassie E, Lasho T, et al. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history [published online ahead of print June 3, 2014]. Eur J Hematol. doi:10.1111/ejh.12389.
7. Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013;122(13):2176-2184.